Article By:
Rod Raynovich
Monday, December 11, 2023 7:39 PM EDT
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Biogen Inc. Beats Q1 Earnings And Revenue Estimates
Bullish on $BIIB
Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink
What are the chances of $BIIB and $TSRO being bought out? They have long been targets, or at least rumored to be, for consolidation.